Europe has several lessons for the US biosimilar market, according to a pharmaceutical executive who spoke during ISPOR 2019.
Europe has several lessons for the US biosimilar market, according to a pharmaceutical executive who spoke during ISPOR 2019.
“You need to have a balance so that there is sustainability in the marketplace,” said Chad Pettit, the executive director of Global Value Access and Policy for Amgen’s Biosimilars Business Unit.
Asked to elaborate in an interview with The Center for Biosimilars® after the panel discussion about biosimilars, he indicated that he meant the different systems that European governments have for reimbursement.
The United Kingdom, for example, has a multi-winner tender system, but other countries, he said, have what he called more extreme procurement mechanisms, such as single tender, winner-take-all systems. Particularly in smaller companies, procurement is “extreme,” he said.
“A single tender procurement mechanism really creates an unbalanced end result,” he said, “creating short-term wins for the country but it’s probably not a long-term win.”
In the United States, CMS set what he called a level playing field for Medicare Part B, but he was more critical of CMS’s decision to reimburse biosimilars differently in the 340B program for hospitals. “We think that that is a distortion of the marketplace and in the long run is not going to benefit the marketplace overall," he said.
During the panel at ISPOR, participants spoke about the need for continued education of physicians and patients. Pettit said overall Amgen was pleased with the FDA’s educational efforts so far, and said all groups play a role, including physician groups, patients groups, medical societies, pharmacists, health plans, and manufacturers. But ultimately, it is the FDA that possesses most of the influence, he said.
Amgen believes that 3 pieces are needed for a long-term market: scientifically appropriate regulatory standards, a level playing field, and scientifically accurate educational outreach.
Asked about the beliefs of different patient groups, with some more in favor of biosimilars than others, Pettit said that gets back to the need for scientifically accurate education. Noting that different groups have different levels of confidence, some might ask questions relating to development, supply, manufacturing, the approval process for prescribing, extrapolation, switching studies between an originator product and its reference product, the difference between a product approved as a biosimilar and a product approved as an interchangeable biosimilar, and pharmacovigilance.
The FDA final rule on interchangeability “gives us certainty on our development programs," he said. "It allows us to have a clear view as we think about development of biosimilar medicines.”
During the panel, he mentioned the cost savings that biosimilars are expected to provide, citing an IQVIA report that said biosimilars saved $7 billion this year and predicts that further use will generate $60 billion in savings by 2023. Those savings "are evidence that the system is working," he said afterwards.
Pettit appeared on the panel with Ha Kung Wong, JD, MBA, a patent attorney with Venable Fitzpatrick, who provided an overview of the post grant review (PGR) and inter partes (IPR) review procedures, which are used for challenging the validity of patents at the patent office, as opposed to more expensive district court litigation.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.